Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | HIF-2 inhibitors in RCC

Hans Hammers, MD, PhD, The University of Texas Southwestern, Dallas, TX, discusses his personal highlights from this year’s meeting. Specifically, he mentions the development of HIF-2 inhibitors in renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.